Perform Another (Advanced) Search

1. Roche Trial Information: : Lupus NephritisRoche - Clinical Trial Protocol Registry and Results
...Official Scientific Title: A randomized, open-label study to compare the effect of CellCept plus corticosteroids, and cyclophosphamide plus corticosteroids followed by azathioprine, on remission rate in patients with lupus nephritis Brief summary: This 2 ...
View Page

2. Roche Trial Information: : Pemphigus Vulgaris (PV)Roche - Clinical Trial Protocol Registry and Results
...CenterWatch Trial information A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) Status: No longer recruiting Protocol number: WX17796 Sponsor ...
...assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to achieve remission with reduced corticosteroid in subjects with pemphigus vulgaris. Brief summary: This study will assess the efficacy and safety ...
View Page

3. Roche Trial Information: : Kidney TransplantationRoche - Clinical Trial Protocol Registry and Results
...by Thomson CenterWatch Trial information A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients. Status: Recruiting Protocol number: ML21740 Sponsor: Hoffmann-La Roche Company division ...
...study comparing the effect of CellCept combined with low dose versus standard dose tacrolimus, and corticosteroids, on kidney function in renal transplantation patients Brief summary: This 2 arm study will compare ...
View Page

4. Roche Trial Information: : Myasthenia Gravis generalisedRoche - Clinical Trial Protocol Registry and Results
...CenterWatch Trial information A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Status: No longer recruiting Protocol number: WX17798 Sponsor: Hoffmann ...
...and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve symptom control with reduced corticosteroid in subjects with myastenia gravis. Brief summary: The efficacy and safety of CellCept(1g po ...
View Page

5. Roche Trial Information: : Kidney TransplantationRoche - Clinical Trial Protocol Registry and Results
...withdrawal of cyclosporine or tacrolimus on renal function in kidney transplant recipients receiving CellCept plus corticosteroids Brief summary: This 2 arm study will recruit kidney transplant patients receiving standard care of calcineurin inhibitors (CNIs, tacrolimus or cyclosporine), CellCept (1.0-1.5 g bid) and corticosteroids. They will either be randomized to continue this regimen, or CNI therapy will be discontinued ...
View Page

6. Roche Trial Information: : Liver TransplantationRoche - Clinical Trial Protocol Registry and Results
...open label study comparing the effect of CellCept with therapeutic drug monitoring, tacrolimus and a corticosteroid-sparing regimen versus fixed dose CellCept, tacrolimus and corticosteroids maintained up to 6 months, on acute rejection and safety in liver transplant patients. Brief ...
View Page

7. Roche Trial Information: : Liver TransplantationRoche - Clinical Trial Protocol Registry and Results
...to Assess the Efficacy and Safety of CellCept (Mycophenolate Mofetil) in Combination With Cyclosporine and Corticosteroids in Preventing Acute Rejection in Pediatric Liver Transplant Patients Status: Completed Protocol number: PA16497 Sponsor ...
...transplant) by pharmacokinetic analysis. The efficacy and safety of CellCept in combination with cyclosporine and corticosteroids will then be evaluated in pediatric liver transplant patients, in the confirmatory phase of the ...
View Page

8.  Study Posting (5169) Trial #140858, Shingles, Newport News, VA
...tolerability of an investigational vaccine (ZOSTAVAX(TM)) that may prevent shingles in patients on chronic Corticosteroids therapy. Shingles (H. zoster) is the same virus that causes chickenpox. The virus can reappear ...
...Inclusion Criteria: Must be 60 years old or older. Must be taking long-term daily corticosteroid medication such as Prednisone, Deltasone, Medrol, Decadron, Cortef, Prelone. Patient Exclusion Criteria: Must not have ...
View Page

9. Roche Trial Information: : Heart TransplantationRoche - Clinical Trial Protocol Registry and Results
...randomized, open-label study to evaluate pharmacokinetic variability of CellCept in association with cyclosporine and corticosteroids in primary orthotopic heart transplant patients Brief summary: This study will evaluate the pharmacokinetic variability (in terms of AUC) of CellCept in association with cyclosporine and corticosteroids, in primary orthotopic heart transplant patients. Within 72 hours of transplantation, patients will be randomized ...
View Page

10. Roche Trial Information: : Breast CancerRoche - Clinical Trial Protocol Registry and Results
...division: Pharmaceutical Official Scientific Title: A randomized, open label study comparing the efficacy of topical corticosteroids or Bepantol in the prophylaxis of hand-foot syndrome in patients receiving oral Xeloda for ...
...colorectal cancer. Brief summary: This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic ...
View Page

11.  Study Posting (77) Trial #140549, Systemic Lupus Erythematosus, Lake Success, NY
...18 years of age • Have a diagnosis of lupus (SLE) • Have been on lupus medication (corticosteroids, immunosuppressive drugs, or anti-malarias) for more than 30 days. Patient Exclusion Criteria You may ...
...the following within 30 days: A live vaccine; or A change in dose of a corticosteroid, other immunosuppressive/immunomodulatory agent, or anti-malarial agent • Have severe lupus kidney disease • Have active ...
View Page

12. Roche Trial Information: : Juvenile Idiopathic ArthritisRoche - Clinical Trial Protocol Registry and Results
...active systemic juvenile idiopathic arthritis (sJIA) who have an inadequate clinical response to NSAIDs and corticosteroids. In Part 1 of the study patients will be randomized 2:1 to receive iv ...
...5 active joints, or >=2 active joints + fever + steroids); • inadequate clinical response to NSAIDs and corticosteroids due to toxicity or lack of efficacy. Exclusion criteria: • wheelchair or bed-ridden; • any other ...
View Page

13.  Study Posting (709) Trial #40288, Stasis Dermatitis, Stanford, CA
...have redness, itching, scaling, and swelling of the lower legs. The study medication contains a corticosteroid foam. We are seeking men and women volunteers over age 18 with mild to moderate ...
View Page

14.  Study Posting (4519) Trial #102320, Rheumatoid Arthritis, Stoke-on-Trent, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

15.  Study Posting (4519) Trial #97611, Rheumatoid Arthritis, Leeds, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

16.  Study Posting (4519) Trial #103507, Rheumatoid Arthritis, Chertsey, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

17.  Study Posting (4519) Trial #97589, Rheumatoid Arthritis, Cambridge, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

18.  Study Posting (4519) Trial #100863, Rheumatoid Arthritis, Birmingham, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

19.  Study Posting (4519) Trial #100470, Rheumatoid Arthritis, Stockholm, Sweden
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

20.  Study Posting (4519) Trial #104298, Rheumatoid Arthritis, Goeteborg, Sweden
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page